3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Breast
1
Conditions
Breast Neoplasms
107
Triple Negative Breast Neoplasms
15
Neoplasm Metastasis
14
Carcinoma, Renal Cell
6
Breast Neoplasms, Male
6
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Breast Diseases
2
Advanced Breast Cancer
2
Unilateral Breast Neoplasms
1
Thrombocytosis
1
Somatostatinoma
1
Skin Diseases
1
Prostatic Neoplasms
1
Primary Non-metastatic Breast Cancer
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
pembrolizumab
24
Paclitaxel
11
Carboplatin
11
Trastuzumab
9
Nivolumab
7
Fulvestrant
6
palbociclib
4
olaparib
4
Taxes
4
Surveys and Questionnaires
4
Methods
4
Early Intervention, Educational
4
Docetaxel
4
Cyclophosphamide
4
Biopsy
4
Bevacizumab
4
pertuzumab
3
lenvatinib
3
fludarabine
3
atezolizumab
3
abemaciclib
3
Tamoxifen
3
Specimen Handling
3
Psychiatric Rehabilitation
3
Metformin
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Interviews as Topic
3
Gemcitabine
3
Counseling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Everolimus
×
Breast
×
Clear all
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled